Home > Publications database > Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections. > print

001     180467
005     20240229145619.0
024 7 _ |a 10.3390/ph15060694
|2 doi
024 7 _ |a pmid:35745613
|2 pmid
024 7 _ |a altmetric:129540797
|2 altmetric
037 _ _ |a DKFZ-2022-01346
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Fresnais, Margaux
|b 0
245 _ _ |a Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections.
260 _ _ |a Basel
|c 2022
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1656328243_4493
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Desorption/ionization (DI)-mass spectrometric (MS) methods offer considerable advantages of rapidity and low-sample input for the analysis of solid biological matrices such as tissue sections. The concept of desorption electrospray ionization (DESI) offers the possibility to ionize compounds from solid surfaces at atmospheric pressure, without the addition of organic compounds to initiate desorption. However, severe drawbacks from former DESI hardware stability made the development of assays for drug quantification difficult. In the present study, the potential of new prototype source setups (High Performance DESI Sprayer and Heated Transfer Line) for the development of drug quantification assays in tissue sections was evaluated. It was demonstrated that following dedicated optimization, new DESI XS enhancements present promising options regarding targeted quantitative analyses. As a model compound for these developments, ulixertinib, an inhibitor of extracellular signal-regulated kinase (ERK) 1 and 2 was used.
536 _ _ |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312)
|0 G:(DE-HGF)POF4-312
|c POF4-312
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a desorption electrospray ionization
|2 Other
650 _ 7 |a drug
|2 Other
650 _ 7 |a mass spectrometry
|2 Other
650 _ 7 |a profiling
|2 Other
650 _ 7 |a quantification
|2 Other
700 1 _ |a Liang, Siwen
|b 1
700 1 _ |a Breitkopf, Marius
|b 2
700 1 _ |a Lindner, Joshua Raoul
|b 3
700 1 _ |a Claude, Emmanuelle
|0 0000-0001-5798-2242
|b 4
700 1 _ |a Pringle, Steven
|b 5
700 1 _ |a Levkin, Pavel A
|b 6
700 1 _ |a Demir, Konstantin
|b 7
700 1 _ |a Benzel, Julia
|0 P:(DE-He78)2b12a7cfc604eb9816670e995f7af508
|b 8
|u dkfz
700 1 _ |a Sundheimer, Julia
|0 P:(DE-He78)303cfc65bbd4cdc79617186d2267d9fd
|b 9
|u dkfz
700 1 _ |a Statz, Britta
|0 P:(DE-He78)5f5223d7faa01a1e1df8a30d85cff5b0
|b 10
|u dkfz
700 1 _ |a Pajtler, Kristian
|0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
|b 11
|u dkfz
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 12
|u dkfz
700 1 _ |a Haefeli, Walter E
|b 13
700 1 _ |a Burhenne, Jürgen
|0 0000-0002-2190-1698
|b 14
700 1 _ |a Longuespée, Rémi
|0 0000-0003-2003-1886
|b 15
773 _ _ |a 10.3390/ph15060694
|g Vol. 15, no. 6, p. 694 -
|0 PERI:(DE-600)2193542-7
|n 6
|p 694
|t Pharmaceuticals
|v 15
|y 2022
|x 1424-8247
909 C O |o oai:inrepo02.dkfz.de:180467
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)2b12a7cfc604eb9816670e995f7af508
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)303cfc65bbd4cdc79617186d2267d9fd
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)5f5223d7faa01a1e1df8a30d85cff5b0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 11
|6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-312
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Funktionelle und strukturelle Genomforschung
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-06-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-06-15
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-06-15
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-06-15
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-06-15
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHARMACEUTICALS-BASE : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-01-15T12:16:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-01-15T12:16:46Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-01-15T12:16:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-29
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b PHARMACEUTICALS-BASE : 2021
|d 2022-11-29
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21